Zoltán Kaló
Zoltán Kaló
1) Center for Health Technology Assessment, Semmelweis University; 2) Syreon Research Institute
E-mail megerősítve itt: semmelweis-univ.hu - Kezdőlap
Hivatkozott rá
Hivatkozott rá
Multiple criteria decision analysis for health care decision making—an introduction: report 1 of the ISPOR MCDA Emerging Good Practices Task Force
P Thokala, N Devlin, K Marsh, R Baltussen, M Boysen, Z Kalo, ...
Value in health 19 (1), 1-13, 2016
Multiple criteria decision analysis for health care decision making—emerging good practices: report 2 of the ISPOR MCDA Emerging Good Practices Task Force
K Marsh, M IJzerman, P Thokala, R Baltussen, M Boysen, Z Kaló, ...
Value in health 19 (2), 125-137, 2016
The life‐years saved by a deceased organ donor
MA Schnitzler, JF Whiting, DC Brennan, KL Lentine, NM Desai, ...
American Journal of Transplantation 5 (9), 2289-2296, 2005
The expanded criterial donor dilemma in cadaveric renal transplantation
MA Schnitzler, JF Whiting, DC Brennan, G Lin, W Chapman, J Lowell, ...
Transplantation 75 (12), 1940-1945, 2003
Cost‐effectiveness of organ donation: evaluating investment into donor action and other donor initiatives
JF Whiting, B Kiberd, Z Kalo, P Keown, L Roels, M Kjerulf
American Journal of Transplantation 4 (4), 569-573, 2004
The cost effectiveness of Apligraf® treatment of diabetic foot ulcers
WK Redekop, J McDonnell, P Verboom, K Lovas, Z Kalo
Pharmacoeconomics 21 (16), 1171-1183, 2003
Diabetic foot ulcers and amputations: estimates of health utility for use in cost-effectiveness analyses of new treatments
WK Redekop, EA Stolk, E Kok, K Lovas, Z Kalo, JJV Busschbach
Diabetes & metabolism 30 (6), 549-556, 2004
Resource use and treatment costs after kidney transplantation: impact of demographic factors, comorbidities, and complications
EG Hagenmeyer, B Häussler, E Hempel, G Grannas, Z Kaló, A Kilburg, ...
Transplantation 77 (10), 1545-1550, 2004
Principles of pharmacoeconomics and their impact on strategic imperatives of pharmaceutical research and development
J Bodrogi, Z Kaló
British journal of pharmacology 159 (7), 1367-1373, 2010
Capacity building for HTA implementation in middle-income countries: the case of Hungary
Z Kaló, J Bodrogi, I Boncz, C Dózsa, G Jóna, R Kövi, Z Pásztélyi, ...
Value in health regional issues 2 (2), 264-266, 2013
Economic evaluation of kidney transplantation versus hemodialysis in patients with end-stage renal disease in Hungary
Z Kaló, J Járay, J Nagy
Progress in Transplantation 11 (3), 188-193, 2001
HTA implementation roadmap in Central and Eastern European countries
Z Kaló, A Gheorghe, M Huic, M Csanádi, FB Kristensen
Health economics 25, 179-192, 2016
Differential pricing of new pharmaceuticals in lower income European countries
Z Kaló, L Annemans, LP Garrison
Expert review of pharmacoeconomics & outcomes research 13 (6), 735-741, 2013
Does therapeutic reference pricing always result in cost-containment?: The Hungarian evidence
Z Kaló, N Muszbek, J Bodrogi, J Bidló
Health Policy 80 (3), 402-412, 2007
Development of health economics in Hungary between 1990-2006
I Boncz, C Dózsa, Z Kaló, L Nagy, B Borcsek, Á Brandtmüller, J Betlehem, ...
The European Journal of Health Economics, S4-S6, 2006
Is there a reason for concern or is it just hype?–A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars
A Inotai, CPJ Prins, M Csanadi, D Vitezic, C Codreanu, Z Kalo
Expert opinion on biological therapy 17 (8), 915-926, 2017
EQUIPT: protocol of a comparative effectiveness research study evaluating cross-context transferability of economic evidence on tobacco control
S Pokhrel, S Evers, R Leidl, M Trapero-Bertran, Z Kalo, H De Vries, ...
BMJ open 4 (11), 2014
Meta-analysis of basiliximab for immunoprophylaxis in renal transplantation
PA Keown, R Balshaw, S Khorasheh, M Chong, C Marra, Z Kalo, A Korn
BioDrugs 17 (4), 271-279, 2003
Cost-benefit approach in evaluating investment into donor action: the German case
L Roels, Z Kalo, D Boesebeck, J Whiting, C Wight
Transplant international 16 (5), 321-326, 2003
Pharmaceutical pricing and reimbursement policies in Slovakia
Z Kaló, E Docteur, P Moïse
OECD, 2008
A rendszer jelenleg nem tudja elvégezni a műveletet. Próbálkozzon újra később.
Cikkek 1–20